-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
FSD Pharma Inc. (NASDAQ:HUGE) Sees Large Growth in Short Interest
FSD Pharma Inc. (NASDAQ:HUGE) Sees Large Growth in Short Interest
FSD Pharma Inc. (NASDAQ:HUGE – Get Rating) saw a large increase in short interest during the month of July. As of July 31st, there was short interest totalling 492,200 shares, an increase of 15.0% from the July 15th total of 428,000 shares. Based on an average trading volume of 69,300 shares, the short-interest ratio is currently 7.1 days. Approximately 2.8% of the company's stock are sold short.
FSD Pharma Stock Up 4.2 %
NASDAQ:HUGE opened at $1.00 on Friday. FSD Pharma has a 12 month low of $0.69 and a 12 month high of $1.94. The company has a 50 day simple moving average of $0.88 and a two-hundred day simple moving average of $0.91.
Get FSD Pharma alerts:FSD Pharma (NASDAQ:HUGE – Get Rating) last announced its quarterly earnings results on Friday, May 13th. The company reported ($0.14) EPS for the quarter.
About FSD Pharma
(Get Rating)FSD Pharma Inc, through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
Featured Articles
- Get a free copy of the StockNews.com research report on FSD Pharma (HUGE)
- 2 Important Retail Stock Battles to Watch
- MarketBeat: Week in Review 8/8 – 8/12
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
Receive News & Ratings for FSD Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FSD Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
FSD Pharma Inc. (NASDAQ:HUGE – Get Rating) saw a large increase in short interest during the month of July. As of July 31st, there was short interest totalling 492,200 shares, an increase of 15.0% from the July 15th total of 428,000 shares. Based on an average trading volume of 69,300 shares, the short-interest ratio is currently 7.1 days. Approximately 2.8% of the company's stock are sold short.
7月份,納斯達克(FSD Pharma Inc.)的空頭股數銷量大幅增長。截至7月31日,空頭股數共有49.22萬股,比7月15日的42.8萬股增加了15.0%。以平均成交量69,300股計算,目前短息比率為7.1天。該公司約2.8%的股票被賣空。
FSD Pharma Stock Up 4.2 %
消防處醫藥股上升4.2%
NASDAQ:HUGE opened at $1.00 on Friday. FSD Pharma has a 12 month low of $0.69 and a 12 month high of $1.94. The company has a 50 day simple moving average of $0.88 and a two-hundred day simple moving average of $0.91.
納斯達克:巨無霸上週五開盤報1美元。FSD Pharma的12個月低點為0.69美元,12個月高位為1.94美元。該公司的50日簡單移動均線切入位在0.88美元,200日簡單移動均線切入位在0.91美元。
FSD Pharma (NASDAQ:HUGE – Get Rating) last announced its quarterly earnings results on Friday, May 13th. The company reported ($0.14) EPS for the quarter.
FSD Pharma(納斯達克:巨無霸評級)最近一次公佈季度收益是在5月13日(星期五)。該公司公佈了該季度每股收益(0.14美元)。
About FSD Pharma
關於消防處藥業
FSD Pharma Inc, through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
FSD Pharma Inc.通過其子公司作為一家制藥研發公司運營。它的主要候選藥物包括正在進行治療新冠肺炎疾病的第二階段臨牀試驗的FSD-201。該公司還專注於Lucid-Topch,一種被發現用於潛在治療抑鬱症等神經精神疾病的精神活性分子;以及Lucid-MS,一種獲得專利的新化學實體,被證明在臨牀前模型中可以防止和逆轉髓鞘降解,這是多發性硬化症的潛在機制。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on FSD Pharma (HUGE)
- 2 Important Retail Stock Battles to Watch
- MarketBeat: Week in Review 8/8 – 8/12
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
- 免費獲取StockNews.com關於FSD Pharma的研究報告(Heavy)
- 值得關注的兩場重要的零售股大戰
- MarketBeat:回顧中的一週2012-8-8
- 什麼是WallStreetBets,他們的目標是什麼股票?
- 機構和分析師推動Jack in the Box走高
- 你能猜到哪個電動車股票打敗了特斯拉嗎?
Receive News & Ratings for FSD Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FSD Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受《消防局醫藥日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對FSD Pharma和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧